Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1Breast 1

Conditions

Sarcoma 4Melanoma 4Breast Neoplasms 3Urinary Bladder Neoplasms 2Osteosarcoma 2Gliosarcoma 2Glioblastoma 2Carcinoma, Merkel Cell 2Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Chondrosarcoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1Bone Neoplasms 1Adenocarcinoma 1

Interventions

Ibandronic Acid 8Gemcitabine 8Doxorubicin 6Cyclophosphamide 6Zoledronic Acid 5Radiation 4Nivolumab 4Irinotecan 4pembrolizumab 3Vincristine 3Temozolomide 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Docetaxel 3Denosumab 3Cisplatin 33-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 3regorafenib 2pegfilgrastim 2Tranexamic Acid 2Trabectedin 2Surveys and Questionnaires 2Sunitinib 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiosurgery 2Quality of Life 2Proton Therapy 2Observation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Neoplasms × poly ICLC × Sarcoma × Clear all
NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

Phase 1 Active not recruiting
14 enrolled
BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡